As it continues to face widespread criticism and condemnation for high drug prices, the pharmaceutical industry is bolstering its lobbying efforts in Washington, according to a Bloomberg Government report.
The political landscape, however, according to Campaign for Sustainable Rx Pricing spokesman Jon Conradi, has seen a significant move away from the status quo.
“There has been a real shift in the political landscape around drug pricing,” Conradi tells Bloomberg. “It’s reached that tipping point that lawmakers in Congress are more concerned on delivering on the demand from American patients and consumers than they are with the big pharma lobbyists and the industry.”
To read the full report on Bloomberg Government, click here.